Close Menu

NEW YORK (GenomeWeb) – Amoy Diagnostics, Premia Holdings, and Loxo Oncology today announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.

As part of the deal, China-based AmoyDx and Tokyo-headquartered Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development. AmoyDx's multigene PCR and next-generation sequencing panels will be used to identify patients with RET genetic alteration.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.